OSE has seen several positive developments in its pipeline over the past few months including the initiation of three new partnered clinical trials: a Phase I study with OSE-127 (Servier), a Phase I study with BI 765063 (previously OSE-172, Boehringer Ingelheim) and a Phase II study with Tedopi in pancreatic cancer (GERCOR). Two milestones were triggered totalling €19.5m, and an extra €7.5m is expected in H119 from BI. OSE also announced a new bispecific platform (pre-clinical), whi
17 Apr 2019
OSE Immunotherapeutics - A change of pace with three new clinical trials
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
OSE Immunotherapeutics - A change of pace with three new clinical trials
OSE Immunotherapeutics SA (OSE:PAR) | 0 0 0.0%
- Published:
17 Apr 2019 -
Author:
Dr Jonas Peciulis -
Pages:
10
OSE has seen several positive developments in its pipeline over the past few months including the initiation of three new partnered clinical trials: a Phase I study with OSE-127 (Servier), a Phase I study with BI 765063 (previously OSE-172, Boehringer Ingelheim) and a Phase II study with Tedopi in pancreatic cancer (GERCOR). Two milestones were triggered totalling €19.5m, and an extra €7.5m is expected in H119 from BI. OSE also announced a new bispecific platform (pre-clinical), whi